4.4 Structure-Activity Relationships and Drug-Receptor Interactions

4.4 Structure-Activity Relationships and Drug-Receptor Interactions

Quick Answer: A drug's three-dimensional structure determines receptor binding, selectivity, and effect. The pharmacophore is the minimum feature set for activity; functional groups tune solubility, lipophilicity, and binding; stereochemistry governs chiral recognition.

Medicinal chemistry's central premise is that biological activity arises from specific molecular interactions. Understanding structure-activity relationships (SAR) lets you predict cross-reactivity, allergy risk, resistance patterns, and prodrug activation - all tested on the FPGEE.

The Pharmacophore

A pharmacophore is the ensemble of steric and electronic features necessary to ensure optimal supramolecular interactions with a biological target. It is the minimum activity template.

Examples:

• beta-lactam pharmacophore: a four-membered beta-lactam ring fused to a five- or six-membered ring, an acyl side chain, and a carboxylate. The strained beta-lactam carbonyl is the electrophile that acylates the bacterial PBP transpeptidase active-site serine.
• ACE inhibitor pharmacophore: a zinc-binding group (sulfhydryl, carboxylate, or phosphonate) plus an N-acyl amino acid backbone that fits the active site.
• opioid pharmacophore: a tertiary amine (usually piperidine), an aromatic ring, and a quaternary carbon linked to a polar group.

SAR Principles

A small structural change can dramatically alter biological activity:

• Adding a methyl can fill a hydrophobic pocket, increasing potency or selectivity, or can introduce a metabolic site.
• Adding a hydroxyl increases polarity, lowers logP, and often reduces CNS penetration.
• Adding a halogen increases lipophilicity, can add halogen-bond interactions, and can slow metabolism (e.g., fluorine at the 5-position of uracil yields 5-fluorouracil, resistant to catabolism).
• Adding a bulky group near a metabolically labile site can block metabolism (steric shielding).

Functional Groups and Their Effects

Drug-Receptor Interaction Forces

Most drugs bind reversibly, allowing dose-response gradients and reversibility of action. Irreversible covalent binding requires synthesis of new receptor or enzyme for recovery - the basis of aspirin's prolonged antiplatelet effect (platelets lack nuclei and cannot make new COX-1).

Receptor Types

Agonist vs Antagonist Structural Requirements

• Agonist must bind AND induce a conformational change; the pharmacophore includes activation features.
• Competitive antagonist binds the same orthosteric site with similar recognition features but lacks the activation features - often a bulkier molecule.
• Inverse agonist stabilizes the inactive conformation and reduces constitutive activity (e.g., some beta-carbolines at the GABA-A receptor).
• Allosteric modulator binds a distinct site; positive (PAM) or negative (NAM) modulators shift the dose-response curve without directly activating the receptor.

Isosterism and Bioisosterism

Isosteres are atoms or groups with the same number of atoms, the same valence electrons, and the same arrangement (Langmuir's original definition). Bioisosteres are atoms or groups with different structures but similar biological activity.

Prodrugs

A prodrug is inactive (or less active) until converted by metabolism or enzymatic cleavage. Rationale: improve oral absorption (acyclovir to valacyclovir), target a specific tissue (levodopa crosses the BBB; dopamine cannot), reduce GI irritation (sulindac), or extend duration.

Stereochemistry

Receptors are chiral - they feel the difference between enantiomers. S-warfarin is 3 to 5 times more potent than R-warfarin. Esomeprazole (S-omeprazole) has less interpatient variability because CYP2C19 polymorphism affects the R-enantiomer more than the S-enantiomer. L-dopa is used rather than D-dopa because only L-amino acid decarboxylase recognizes it.

Applicability to Therapy Decisions

• Cross-reactivity and allergy: the beta-lactam ring is the major allergenic determinant. Penicillins and cephalosporins cross-react approximately 1 to 10% (higher with earlier-generation cephalosporins). Carbapenems cross-react < 1% with penicillins. Monobactams (aztreonam) have essentially no cross-reactivity with penicillins (the exception is ceftazidime, which shares a side chain with aztreonam).
• Resistance patterns: structural modification of the beta-lactam side chain (e.g., the methoxyimino group in third-generation cephalosporins) extends the spectrum and confers beta-lactamase stability.
• Prodrug design explains therapeutic failures: codeine is ineffective in CYP2D6 poor metabolizers; clopidogrel is ineffective in CYP2C19 poor metabolizers.
• Stereo-specific toxicity: thalidomide - one enantiomer is sedative, the other teratogenic, but in vivo racemization means either enantiomer can cause limb defects.

Clinical Synthesis

When a patient reports penicillin allergy, the medicinal chemistry of the beta-lactam ring lets you anticipate which alternative cephalosporin is safer. When a CYP2D6 poor metabolizer needs an analgesic, recognizing codeine as a prodrug prevents a therapeutic failure. When a patient on clopidogrel needs an oral antifungal, knowing omeprazole is a CYP2C19 inhibitor (and a chiral-switch drug with significant polymorphism exposure) lets you anticipate reduced clopidogrel activation. The FPGEE tests exactly these linkages between chemistry and clinical decisions.

---

Master the pharmacophore concept, the binding force hierarchy, the major functional group effects, the prodrug activation table, and the clinical implications of beta-lactam cross-reactivity and chiral switches. These are the topics most reliably converted into FPGEE points.